Skip to content
Calculator
Guide

Can peptides help after surgery? What the studies and surgeons say

Last updated: November 4, 2026 · 9 min read · By the Grey Peptides Editorial Board

Quiet hospital hallway with neatly arranged empty medical beds under bright ceiling lights
Photo by adrian vieriu on Pexels
Grey Peptides
Grey Peptides Editorial Board
Every status on this page carries the date it was checked. How we work
Key takeaways
  • No peptide is approved to speed recovery from surgery. A few have been tested around operations or injuries: teriparatide in fractures, collagen supplements after ligament and rotator cuff repair, and a copper peptide cream after laser skin treatment. Results are modest or mixed.
  • BPC-157 and TB-500, the peptides most sold for recovery, have no human surgical studies. Their evidence is in animals.
  • The practical issue is safety and disclosure: unregulated products, unknown interactions with anaesthesia and other drugs, and GLP-1 drugs' effect on stomach emptying. Tell your surgical team about every peptide you take.

What is being promised

Recovery from surgery is a natural target for peptide marketing. BPC-157, for example, is increasingly used by clinicians and athletes for musculoskeletal injuries despite lacking FDA approval, on the strength of animal studies 1. The question for anyone facing an operation is simpler: has any of this been tested in people recovering from surgery, and what are the risks of trying it?

Why healing after surgery is hard to speed up

The one peptide tested in a randomised trial of fracture healing shows the scale of what is at stake. In that trial, a wrist fracture took a median of 9.1 weeks to bridge on X-ray on placebo and 7.4 weeks on the better-performing dose, and even that gap came from a post hoc analysis 2. A product claiming to cut weeks or months from recovery needs trials like that one, and for the peptides most marketed for recovery no such trial exists in people.

What has actually been tested

Ranked by the most relevant human evidence we could find, as of October 27, 2026. Grades come from our encyclopedia and follow the rubric on our methodology page.

PeptideTested after surgery or injury in people?What was foundGrade
Teriparatide (approved for osteoporosis)Yes, in fracture healing trialsMixed: one dose shortened healing in a wrist-fracture trial, the other did not; pooled trials show faster unionHigh
Collagen peptides (supplement)Yes: one randomised trial after ACL reconstruction and one after rotator cuff repair, mostly multi-ingredient productsA cautiously positive, low-certainty signal as an add-on to rehabilitationMedium
GHK-Cu (topical)After laser skin resurfacingPatients rated skin better; investigator measures did not differMedium
Thymosin beta-4 (topical, investigational)In chronic venous ulcers, not surgical woundsA dose-escalation trial whose cited report gives the design and enrolment, not results; not approvedMedium
BPC-157NoAnimal studies only for surgical healing; three small uncontrolled human studies (30 people), none after surgeryLow
TB-500NoNo human study of the fragmentLow

Bone: teriparatide, an approved drug with mixed results

Teriparatide, a fragment of parathyroid hormone, is approved for osteoporosis, and animal studies suggested it could speed fracture repair. The test in people was a randomised, double-blind trial in 102 postmenopausal women with wrist fractures treated without surgery, given placebo or one of two teriparatide doses for eight weeks. The median time to bridging of the fracture on X-ray was 9.1 weeks on placebo, 7.4 weeks on the lower dose and 8.8 weeks on the higher dose. The trial's primary comparison, the higher dose against placebo, was not significant; the lower dose's faster healing came from a post hoc analysis that the authors said should be interpreted with caution 2.

Later trials have added to the picture. A 2026 systematic review and meta-analysis of anti-osteoporosis drugs and fracture healing, covering 28 trials and 5,085 patients (12 of them pooled), found that teriparatide significantly shortened time to fracture union compared with control, with no significant difference in delayed union rates, and bisphosphonates did not change time to union; the authors concluded that teriparatide might reduce time to union for osteoporotic fractures and that further prospective evidence is needed 3. Teriparatide is not approved to speed fracture healing, and whether it is used after a fracture or orthopaedic surgery is a decision for the treating surgeon. Our teriparatide entry covers its approved uses and label warnings.

Tendons and ligaments: collagen supplements, not injections

After tendon and ligament surgery, collagen is the peptide product with trials. A 2026 systematic review found six studies, three of them direct: one randomised trial after anterior cruciate ligament reconstruction, one after rotator cuff repair, and a pilot of injected low-molecular-weight peptides in partial supraspinatus tears. Collagen-based interventions were associated with improvements in pain, function, analgesic use or imaging, but most oral products contained several ingredients, and the authors called the signal cautiously positive as an adjunct to rehabilitation or postoperative care, with sparse, low-certainty evidence 4. Our ranking of peptides for tendon and ligament injuries sets out the wider evidence, including how little exists for BPC-157 and TB-500.

Skin and wounds: a copper peptide cream and a protein in trials

The clearest post-procedure evidence for a cosmetic peptide is small. In a randomised study of carbon dioxide laser resurfacing around the mouth (13 patients completed), those using a copper tripeptide (GHK-Cu) regimen rated their skin quality higher, but computer analysis and blinded evaluators found no difference in redness, wrinkles or overall skin quality 5. Thymosin beta-4, the protein TB-500 is based on, entered a multicentre, placebo-controlled, dose-escalation trial as a topical treatment for chronic venous leg ulcers; the cited 2007 report describes the design, with 21 patients enrolled in the first dose group, and gives no results 6. It has not been approved for any wound, and leg ulcers are not surgical incisions.

BPC-157 and TB-500: no surgical studies in people

The two peptides most sold for recovery have not been studied in people after surgery. A 2026 systematic review found BPC-157's human record to be three small uncontrolled studies, 30 people in all: a knee-injection chart review, an interstitial cystitis pilot and a two-person intravenous safety pilot, all of poor methodological quality 7 8 9; a 2025 orthopaedic systematic review found 35 of its 36 studies were preclinical 1. TB-500, the short synthetic fragment, has no human study; trials of the full thymosin beta-4 protein are a different molecule 10. The closest thing to a surgical model is a 2026 study in 32 rats whose repaired Achilles tendons were treated with BPC-157, TB-500, both or nothing for four weeks: only TB-500 alone produced a significant gain in load to failure, BPC-157 alone did not reach significance on the total histology scores, and the combination added nothing 11. Animal studies of faster healing are a reason to run trials, not evidence that the peptides help people recover from operations. Both are prohibited at all times by WADA (BPC-157 under S0, TB-500 under S2) 10 12. Neither is FDA-approved, and neither appears in any category of FDA's 503A bulk substances list (updated May 14, 2026) 13. FDA's compounding advisory committee discussed both in July 2026 and, by the vote counts law firms reported, recommended both 8 to 6; FDA's meeting page posts no tallies 14 15.

What surgeons worry about

Three concerns stand out with unregulated peptides around an operation. The first is simply not knowing: the orthopaedic review of BPC-157 warned that adverse effects are possible from unregulated manufacturing, contamination and unknown clinical safety 1, and we found no study of how BPC-157, TB-500 or most other research peptides interact with anaesthetic drugs, antibiotics, blood thinners or the medicines given after surgery. Our Interaction Matrix shows how much has been reviewed for each peptide.

The second is biological. The same review describes BPC-157 acting on pathways involved in cell growth and angiogenesis (blood vessel growth) 1, and that raises questions for people with a history of cancer; our article on BPC-157 and angiogenesis sets out what is and is not known.

The third is specific and on the labels. Semaglutide (Wegovy) and tirzepatide (Zepbound) delay stomach emptying, and their labels report rare postmarketing cases of pulmonary aspiration in patients undergoing elective procedures under general anaesthesia or deep sedation who had food left in the stomach despite following fasting instructions; the labels say the data are insufficient to say whether changing fasting or pausing the drug reduces the risk, and tell patients to inform their healthcare providers before any planned procedure 16 17. Our guide to GLP-1s before surgery covers the 2024 multi-society guidance, which says most patients can continue but asks the team to know 18.

Clinic and telehealth 'recovery protocols'

A clinic or telehealth service offering a peptide 'recovery protocol' does not change the product's regulatory status. BPC-157 and TB-500 are not FDA-approved, and neither is in any category of FDA's 503A bulk substances list 13. Our article on what 'research use only' means covers products sold under that label. If a clinic offers a peptide around your operation, ask what exactly it is, who made it, whether it comes from a licensed pharmacy, and whether your surgeon knows. A clinic that will not answer those questions is telling you something.

On October 30, 2026, HHS, FDA's parent department, published a notice saying it will not take enforcement action against 503A pharmacy compounding of BPC-157 and TB-500 under the forms, routes and conditions in its Appendix B 19. The policy is non-binding, labelled a draft and open to revision; FDA has not added either to the 503A Bulks List or Category 1, and the policy does not cover research-use-only sales (our fact check).

Questions to take to your pre-operative appointment

  • I take these peptides or supplements (name, amount, last dose). Should I stop any of them before surgery, and when?
  • Could any of them affect anaesthesia, bleeding, infection risk or the medicines I will be given afterwards?
  • I take a GLP-1 drug for diabetes or weight. Do you want me to change anything, such as following a liquid diet the day before?
  • When is it safe to restart anything I stop?
  • For bone or orthopaedic surgery: is there anything with real evidence, such as osteoporosis treatment or a rehabilitation plan, that I should be doing?

Tell your team: disclosure matters

Many people use supplements and other products before surgery without mentioning them. In a 2002 US survey of elective surgical outpatients at 16 hospitals, 67% reported using complementary products in the two weeks before surgery (27% herbs, 39% dietary supplements, 54% vitamins), and 34% used products that could potentially interact with anaesthetics or inhibit blood clotting 20. That survey predates the peptide boom, but the lesson applies: your anaesthetist and surgeon can only plan around what they know.

Before any operation, tell the team exactly what you take, including research peptides, compounded products and anything injected, with the product name, the amount and when you last used it. Bring the vial or label if you can. Ask whether anything should be stopped and when it is safe to restart. Do not stop a prescribed medicine on your own, and do not start a new peptide around surgery without discussing it.

What does help recovery

What helps depends on the operation, and the surgical team's plan for wound care, activity, rehabilitation and follow-up is the place to start; ask what evidence sits behind each part of it. For a fracture in someone with osteoporosis, the surgeon may consider osteoporosis treatment, which is where teriparatide's evidence fits 3. For tendon and ligament repairs, the collagen trials above tested supplements alongside rehabilitation, not instead of it 4.

Frequently asked questions

What are the best peptides for post-surgery recovery?

No peptide is approved to speed surgical recovery. Teriparatide has mixed evidence in fracture healing, and collagen supplements a cautiously positive, low-certainty signal from one trial each after ACL reconstruction and rotator cuff repair. BPC-157 and TB-500 have no human surgical studies.

Can I take BPC-157 after surgery?

It has not been tested in people recovering from surgery, it is not FDA-approved, and its interactions with anaesthetic and post-operative drugs are unknown. Discuss anything you plan to take with your surgical team.

Should I tell my surgeon about peptides?

Yes. Tell your surgeon and anaesthetist about every peptide, supplement and compounded product you use, with the amount and when you last took it, and ask what to stop and when to restart.

Do I need to stop Ozempic or Wegovy before surgery?

Not necessarily. Multi-society guidance from October 2024 says most patients can continue, with extra precautions such as a liquid diet the day before for those at higher risk. The labels ask you to tell your healthcare providers about any planned procedure.

Sources

  1. Vasireddi, N., et al. (2025). Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J, 21(4), 485-495. PMID: 40756949
  2. Aspenberg, P., et al. (2010). Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res, 25(2), 404-14. PMID: 19594305
  3. Agarwal, N., et al. (2026). The effects of anti-osteoporotic medication on fracture healing and outcomes: a systematic review and meta-analysis. Lancet Healthy Longev, 7(5), 100827. PMID: 42229491
  4. Latini, L., et al. (2026). Clinical evidence for low-molecular-weight collagen peptides in tendon and ligament tears: a systematic review with narrative synthesis. Front Med (Lausanne), 13, 1891011. PMID: 42666580
  5. Miller, T. R., et al. (2006). Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg, 8(4), 252-9. PMID: 16847171
  6. Guarnera, G., et al. (2007). Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study on safety, tolerability, and enhancement on healing. Ann N Y Acad Sci, 1112, 407-12. PMID: 17495250
  7. Poolton, J. T., et al. (2026). Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg, 92(3). PMID: 42885452
  8. Lee, E., et al. (2021). Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med, 27(4), 8-13. PMID: 34324435
  9. Lee, E., et al. (2025). Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med, 31(5), 20-24. PMID: 40131143
  10. Grey Peptides encyclopedia entries for BPC-157 and TB-500: regulatory status, WADA 2026 status (BPC-157 S0; thymosin beta-4 and its derivatives e.g. TB-500, S2), and the TB-500 note that full-length thymosin beta-4 trials tested the 43-amino-acid protein, not the fragment. Read October 27, 2026.
  11. Biçer, O., et al. (2026). Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg, 37(3), 822-837. PMID: 42542926
  12. World Anti-Doping Agency. The 2026 Prohibited List, in force January 1, 2026: S0 (non-approved substances, BPC-157 named) and S2 (peptide hormones, growth factors, related substances and mimetics). WADA
  13. U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (Categories 1 to 3): BPC-157 and TB-500 appear in no category. Updated May 14, 2026; re-read October 27, 2026. FDA
  14. McDermott (law firm). PCAC backs majority of peptides in two-day public meeting (July 27, 2026): BPC-157 and TB-500 each recommended 8 to 6 with one abstention, as reported; a law-firm summary, not an FDA record. Read October 27, 2026.
  15. US FDA. Pharmacy Compounding Advisory Committee, July 23-24, 2026 meeting page: briefing documents, questions, agenda, roster and presentations; no minutes or vote tallies posted (content current as of August 6, 2026); read October 27, 2026. FDA
  16. Novo Nordisk. Wegovy (semaglutide) US prescribing information, section 5.10 Pulmonary Aspiration During General Anesthesia or Deep Sedation (DailyMed set ee06186f, version 19, effective June 18, 2026); re-read October 27, 2026. DailyMed
  17. Eli Lilly. Zepbound (tirzepatide) US prescribing information, section 5.9 Pulmonary Aspiration During General Anesthesia or Deep Sedation (DailyMed set 487cd7e7, version 40, effective August 28, 2026); read October 27, 2026. DailyMed
  18. American Society of Anesthesiologists. New multi-society clinical practice guidance released (GLP-1 receptor agonists before elective surgery). News release, October 29, 2024 (last updated February 18, 2025). Read October 27, 2026. ASA
  19. US Department of Health and Human Services, Office of the Secretary. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register 91 FR 68526, October 30, 2026; docket HHS-OASH-2026-0496 (non-binding; labelled a draft). Read November 4, 2026. Federal Register
  20. Norred, C. L. (2002). Complementary and alternative medicine use by surgical patients. AORN J, 76(6), 1013-21. PMID: 12528489

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.

All articles

New guides and rule changes, by email

One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.

We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead